Do Not Continue Cefazolin for This Resistant S. aureus Bone Infection
You should switch from cefazolin to an alternative antibiotic immediately. The resistance pattern you describe—penicillin, clindamycin, and erythromycin resistance—strongly suggests this is either methicillin-resistant S. aureus (MRSA) or a methicillin-susceptible strain with inducible clindamycin resistance (MLSb phenotype). In either scenario, cefazolin is inappropriate.
Why Cefazolin Should Not Be Continued
The Critical Resistance Pattern
The combination of erythromycin and clindamycin resistance in S. aureus indicates one of two concerning scenarios:
Inducible clindamycin resistance (MLSb phenotype): Even if the strain tests as methicillin-susceptible, the erythromycin resistance suggests potential cross-resistance to all beta-lactams through inducible mechanisms 1, 2, 3, 4.
MRSA masquerading as susceptible: Despite cephalosporins showing in vitro susceptibility in some MRSA strains, cross-resistance exists and cephalosporins are not considered useful in methicillin-resistant infections 5, 6.
Guideline-Based Contraindications
The IDSA explicitly warns that despite antibiotic susceptibility results indicating methicillin-resistant, coagulase-negative staphylococci are susceptible to cephalosporins, cross-resistance exists, and cephalosporins are not considered to be useful 5. This principle extends to all staphylococcal infections with concerning resistance patterns.
For osteomyelitis specifically, the 2011 IDSA MRSA guidelines state that clindamycin has "potential of cross-resistance and emergence of resistance in erythromycin-resistant strains; inducible resistance in MRSA" 2. When both erythromycin and clindamycin resistance are present, this signals a high-risk resistance mechanism.
Recommended Treatment Algorithm
Step 1: Immediate Antibiotic Switch
Switch to vancomycin 15-20 mg/kg IV every 8-12 hours (with therapeutic drug monitoring targeting trough 15-20 mcg/mL) 2, 7.
Alternative options if vancomycin is contraindicated:
Step 2: Confirm Methicillin Susceptibility
Request the laboratory perform:
- Cefoxitin disk diffusion or oxacillin MIC testing (standard methicillin resistance screening)
- PBP2a latex agglutination or mecA PCR if available—these detect methicillin resistance even in oxacillin-susceptible MRSA (OS-MRSA), a rare but documented phenotype that can cause beta-lactam treatment failure 8
- D-test for inducible clindamycin resistance if not already performed
Step 3: Duration and Adjunctive Therapy
For osteomyelitis:
- Minimum 8 weeks of IV therapy 2, 7
- Consider adding rifampin 600 mg daily or 300-450 mg twice daily after bacteremia clears (if present), though this should be added only after clearance of any concurrent bacteremia 2, 7
- Surgical debridement is the mainstay of therapy and should be performed whenever feasible 2
Common Pitfalls to Avoid
The "Susceptible on Paper" Trap
The most dangerous pitfall is continuing cefazolin based solely on automated susceptibility reporting. The resistance pattern you describe (penicillin + clindamycin + erythromycin) is a red flag that overrides standard susceptibility results for cephalosporins 5, 2.
The Penicillin Allergy Exception
Even the European and IDSA guidelines that list cefazolin as an alternative for penicillin-allergic patients explicitly state this applies only to "non-anaphylactic reactions" and only for confirmed methicillin-susceptible strains without concerning resistance patterns 6. Your case does not meet these criteria.
Clinical Failure as Confirmation
One case report documented OS-MRSA septic bursitis where the patient failed cefazolin therapy despite initial susceptibility testing, requiring switch to trimethoprim-sulfamethoxazole for cure 8. Do not wait for clinical failure—the resistance pattern alone warrants immediate change.
The Evidence Hierarchy
While some older studies suggest cefazolin has activity against MSSA 9, 10, 11, and recent data show it remains effective for typical MSSA infections 12, 13, 14, none of these apply to your scenario. The combination of clindamycin and erythromycin resistance fundamentally changes the risk-benefit calculation.
The 2015 ESC guidelines explicitly state that cephalosporins should not be used for methicillin-resistant staphylococcal endocarditis despite in vitro susceptibility 6. While your case is osteomyelitis rather than endocarditis, the same principle of avoiding cephalosporins in high-risk resistance patterns applies to all serious staphylococcal infections.
Bottom line: The resistance pattern indicates either MRSA or a high-risk MSSA phenotype. Switch to vancomycin, daptomycin, or linezolid immediately while awaiting confirmatory testing.